It's funny that you didn't bold the word "mild". M
Post# of 72444

Primary endpoint: Percentage of subjects with ≥ 2 point improvement in IGA rating in patients with mild to moderate chronic plaque psoriasis.
PR: Cellceutix Phase 2 Trial of Prurisol for Mild to Moderate Psoriasis Meets Primary Endpoint
Please explain why the trial failed.


Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
